Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | MASP2 | O00187 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | S100A9 | P06702 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26090258 | 0.84 | ADRA1D (0.46) | ADRA1DMASP2MRGPRX4GPR35HPGD | |
| SCHEMBL26087825 | 0.82 | HSP90AB1 (0.49) | ADRA1DMASP2MRGPRX4RORCGPR35 | |
| SCHEMBL48901 | 0.81 | IDO1 (0.43) | CNR1CTBP2 | |
| SCHEMBL12135664 | 0.80 | GPR35 (0.47) | ADRA1DMRGPRX4GPR35HPGD | |
| SCHEMBL16235634 | 0.79 | ADRA1D (0.42) | ADRA1DMASP2MRGPRX4RORCGPR35 | |
| SCHEMBL2161049 | 0.79 | MRGPRX4 (0.43) | ADRA1DMRGPRX4GPR35NR3C1NR3C2 | |
| SCHEMBL30748474 | 0.76 | ADRA1D (0.41) | ADRA1DMASP2MRGPRX4RORCGPR35 | |
| SCHEMBL30646925 | 0.76 | ADRA1D (0.43) | ADRA1DMRGPRX4NR3C1NR3C2S100A9 | |
| SCHEMBL2160824 | 0.76 | ADRA1D (0.43) | ADRA1DMRGPRX4NR3C1NR3C2S100A9 | |
| SCHEMBL13226822 | 0.76 | CYP2A6 (0.48) | ADRA1DMRGPRX4GPR35NR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4573077-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024249252-A1 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024040235-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |